表紙
市場調査レポート

世界のジェネリック薬市場

World Generic Market Report 2013

発行 Espicom Business Intelligence 商品コード 234936
出版日 ページ情報 英文 492 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
世界のジェネリック薬市場 World Generic Market Report 2013
出版日: 2013年06月28日 ページ情報: 英文 492 Pages
概要

当レポートでは、世界のジェネリック薬市場の動向を企業および国別に調査分析し、ジェネリック薬産業における主要動向および課題、主要27社の企業概要、関連ニュース、製品データ、財務情報、主要12ヵ国の市場規模、展望および予測、知的財産権の動向、価格・償還、製造動向などをまとめ、2巻構成にて概略下記の構成でお届けいたします。

第1巻:世界市場の概要・企業プロファイル

  • 産業の現状
    • ジェネリック薬:統合・M&A
    • ジェネリック薬とブランド薬:M&A
    • ブランド薬産業の「特許の崖(patent cliff)」
  • 主要ジェネリック薬製造業者
  • バイオシミラー
    • 米国
    • FDA:ユーザーフィースキームを議会に送付
    • 欧州
    • 市場にける受容
    • 今後のディベロッパー
  • 米国における現在の課題
    • 承認済みジェネリック薬
    • リバースペイメント
    • 独占性の共有
    • GDUFA
    • FDAの査察と警告書
  • EUにおける現在の課題
    • EC:医薬品部門への最終報告書をリリース
    • 特許関連の和解のモニタリング
    • EC:医薬品企業に抜き打ち査察
    • ジェネリック薬の出荷の差し押さえ
    • カナダ・EUの「CETA(Comprehensive Economic and Trade Agreement)」
  • WTOとジェネリック薬へのアクセス
    • TRIPSの後発発展途上国への適用:2002年
    • 2003年合意、など
  • 主要企業
    • Actavis
    • Apotex
    • Aspen Pharmacare
    • Aurobindo
    • Cipla
    • Dr. Reddy's Laboratories
    • Egis
    • Hospira
    • Impax Laboratories
    • Krka
    • Lannett
    • Lupin
    • Mylan
    • Par Pharmaceutical Companies
    • Perrigo
    • Ranbaxy Laboratories
    • Gedeon Richter
    • Sandoz
    • Sanofi
    • 沢井製薬
    • Simcere Pharmaceutical
    • Stada Arzneimittel
    • Sun Pharmaceutical Industries
    • Teva Pharmaceutical Industries
    • Watson Pharmaceuticals
    • Wockhardt
    • Zydus Cadila
      • イントロダクション
      • 企業情報
      • 製品
      • 財務情報、など

第2巻:国別市場

  • 概要
  • 国別市場
    • オーストラリア
    • ブラジル
    • カナダ
    • フランス
    • ドイツ
    • イタリア
    • 日本
    • ロシア
    • スペイン
    • スイス
    • 英国
    • 米国
      • イントロダクション
      • 医薬品市場
      • ジェネリック薬市場
        • 規模
        • 展望・予測
        • 知的財産権
        • 価格・償還
        • 製造、など

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 978-1-909584-27-3

Abstract

A complete global analysis of the prospects for markets and companies in this dynamic industry sector

Features and benefits of this thoroughly-researched and highly-regarded management report:

  • High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your business planning and decision-making process
  • Global coverage - with 74 country markets profiles: Scope opportunities for new investment or sales growth, with detailed historical data and forecasts on the leading developed economies as well as key emerging markets from Africa, the Americas, Asia, Emerging Europe, and the Middle East
  • Issue driven: Understand the latest company, product, and regulatory developments
  • Company Insight - with the 26 leading companies reviewed: Who's working with whom? Who's suing whom? Who's up, who's down? Assess the activities, strategies and market position of your competitors, partners and clients
  • Flexible formats: Available in pdf format with online access included in the price. Cost-effective distribution licences can ensure you get the best from your investment
  • Biosimilars: Coverage of the fast developing biosimilars market
  • Easily understand the threats and opportunities that are shaping this rapidly evolving sector!

Industry Issues

If the branded pharmaceutical industry was facing a patent cliff it is now teetering on the edge of it. Ironically, it is the world's best selling drug, Lipitor, which exemplifies the trend. Despite still having patent protection, Pfizer has been unable to stem the tide of interest and pressure from a number of companies, Ranbaxy being chief amongst them. Despite pressure on prices in many markets, the generic sector continues to thrive with increased sales across the board in 2012. The maturity of the sector can also be seen in the size of the businesses: there are now 18 generic companies with revenues in excess of US$1,000 million, 6 more than in 2008/09..

Company Assessments

In recent years there has been a trend towards consolidation, both within the generics industry itself, and between the generics industry and the branded industry. This has been a trend born of necessity, reflecting both the difficult economic environment and the slowdown in development of innovative drugs. Without doubt, the most important and largest acquisition to have taken place over the last year has been the merger between Watson Pharmaceuticals and Actavis. The merger has created a company with revenues for the year ended 31st December 2012 of just over US$5.9 billion.

Market Analysis

The generic market is experiencing two opposing trends driven by the global downturn. On one hand, the use of generics is increasing due to their cost-effectiveness and adoption has accelerated in markets where branded prescribing was dominant. On the other hand, the squeeze on government spending has not left generics untouched, with many countries lowering generic prices through cuts in reimbursement rates or contract tendering with a resultant squeeze on margins.

Industry consolidation, new market opportunities, the latest on biosimilars plus much, much more!

This leading report, now in its 11th year of publication, draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues. This extensive data set is interpreted and evaluated by the editors to provide a complete and compelling review of the whole sector.

Key facts, issues and questions

  • Which branded companies are taking an increased interest in the dynamic generics market?
  • How are generics companies faring in the recession?
  • Which companies are involved in the latest legal challenges and litigation?
  • Biosimilars get ever closer - what are the latest regulatory updates?
  • Which country markets have experienced the largest growth in 2012 and which are forecast to be the fastest growers?
  • Negative perceptions of generic drug quality - which markets are most exposed?
  • Pricing pressures - which markets are facing the greatest pressures on pricing from the government?
  • State support for local production - which markets are set to benefit from increased government support?

The generic sector is fast growing, driven by demand for cost-effective medicines and new availability of high value products

Top 30 Global Generic Drug Markets By Growth
(local currency y-o-y 2012)

Source: BMI

XX Commercial in Confidence.

The interactive web-based version of The World Generic Market Report will rapidly identify the information you are looking for.

  • Export data and charts for inclusion in presentations
  • Address all questions across the product in your library
  • Share access with colleagues near and far with a flexible and cost-effective distribution licence

About Espicom Business Intelligence

Espicom Business Intelligence is a UK-based company with a 30-year pedigree providing business intelligence on Medical Devices, Pharmaceuticals & Healthcare and Therapeutics across global markets.

Table of Contents

Volume 1: Company Profiles

FOREWORD

THE STATE OF THE INDUSTRY

  • Generic Consolidations, Mergers and Acquisitions
  • Generic and Branded Acquisitions and Agreements
  • The branded industry's ‘patent cliff'

MAJOR GENERIC MANUFACTURERS

BIOSIMILARS

  • In the USA
    • Another option: file a full BLA ?
    • The development of a US biosimilar pathway
    • The BCPIA
    • Implementation of the BCPIA
    • FDA guidance documents published
    • Innovators make their case to the FDA
  • Biosimilar User Fee Programme
  • Virginia passes biosimilar legislation
  • GPhA: Grant Thornton study shows need for biosimilar competition
  • In Europe
    • EMA Guideline Documents
    • EMA to accept biosimilar reference medicines from outside the EEA
  • Sandoz: new study shows biosimilars can save EU healthcare systems up to 33 billion euros by 2020
  • Elsewhere

CURRENT ISSUES IN THE USA

  • Authorised generics
    • FDA issues direct final rule regarding listing of authorised generics
  • Pay for delay agreements
  • Shared exclusivity
  • GDUFA
  • Drug shortages
  • Generic drug labelling
  • Study finds majority of generics' warning labels differ from branded equivalents

CURRENT ISSUES IN THE EUROPEAN UNION

  • EC releases final report into pharmaceutical sector
  • Monitoring of patent settlements
    • EC Statement of Objections
    • European Parliament votes in favour of European unitary patent
    • EU committee votes on Transparency Directive
  • Free Trade Agreements

CURRENT ISSUES IN THE REST OF THE WORLD

  • The WTO and access to generics
    • TRIPS patent ruling on least-developed countries, 2002
    • 2003 Agreement
  • US PEPFAR Programme
  • The Medicines Patent Pool
  • Patent Laws
    • India

COMPANIES

  • ACTAVIS
    • Introduction
    • Company Details
      • Watson Pharmaceuticals
      • Actavis Group
      • Acquisition and merger
      • Operations - Watson Pharmaceuticals
      • Operations - Actavis
    • Products
      • Generics
      • Brand Products
      • Distribution
    • Financials
      • Segment Results
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation News
  • APOTEX
    • Introduction
    • Company Details
    • Products
      • ApoTriavir
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation
  • ASPEN PHARMACARE
    • Introduction
    • Company Details
    • Products
      • HIV/AIDS drugs
    • Financials
      • Regional Financial Breakdown
    • Recent Developments
      • Recent Company News
  • AUROBINDO PHARMA
    • Introduction
    • Company Details
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation
  • CIPLA
    • Introduction
    • Company Details
    • Manufacturing facilities
      • Products
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation
  • DR. REDDY'S LABORATORIES
    • Introduction
    • Company Details
    • Products
    • Financials
      • Segment Data
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation
  • EGIS
    • Introduction
    • Company Details
    • Products
    • Financials
      • Regional sales breakdown
    • Recent Developments
      • Recent Litigation
  • HOSPIRA
    • Introduction
    • Company Details
      • Project Fuel
    • Manufacturing facilities
    • Products
      • Product Development
    • Financials
      • Results by region
    • Recent Developments
      • Recent Agreements
      • Recent Company News
  • IMPAX LABORATORIES
    • Introduction
    • Company Details
      • Alliance and collaboration agreements
    • Products
    • Financials
      • Sales by division
    • Recent Developments
      • Recent Company News
      • Recent Litigation
  • KRKA
    • Introduction
    • Company Details
      • Krka Group development strategy
    • Products
      • Marketing authorisations
      • Prescription pharmaceuticals
    • Financials
      • Results by Regions
      • Product and Service Groups
    • Recent Developments
      • Recent Company News
  • LANNETT
    • Introduction
    • Company Details
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation News
  • LUPIN
    • Introduction
    • Company Details
    • Products
    • Financials
      • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation
  • MYLAN
    • Introduction
    • Company Details
    • Products
    • Financials
      • Segment Data
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation News
  • PAR PHARMACEUTICAL COMPANIES
    • Introduction
    • Company Details
    • Products
    • Financials
      • Segment Data
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Agreements
      • Recent Litigation News
  • PERRIGO
    • Introduction
    • Company Details
    • Products
    • Financials
      • Segment Sales
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation
  • RANBAXY LABORATORIES
    • Introduction
    • Company Details
      • Acquisition by Daiichi Sankyo
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
  • GEDEON RICHTER
    • Introduction
    • Company Details
    • Products
    • Research and development
    • Female healthcare
    • Financials
      • Markets - pharmaceutical segment
    • Recent Developments
      • Recent Company News
      • Recent Agreements
      • Recent Litigation
  • SANDOZ
    • Introduction
    • Company Details
    • Products
    • Financials
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation
  • SANOFI
    • Introduction
    • Company Details
      • Zentiva
      • Medley
      • Kendrick
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
  • SAWAI PHARMACEUTICAL
    • Introduction
    • Company Details
      • Medium-term Business Plan M1 TRU ST
      • M1 TRU ST 2015
      • Sawai reviews Japanese generic drug market
    • Products
      • New government supply rules, 2006
    • Financials
    • Recent Developments
    • Recent Company News
  • SIMCERE PHARMACEUTICAL
    • Introduction
    • Company Details
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation
  • STADA ARZNEIMITTEL
    • Introduction
    • Company Details
      • Build the future
    • Products
      • Biosimilars
    • Financials
      • Segment Data
      • Geographic Segment Data
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
  • SUN PHARMACEUTICAL INDUSTRIES
    • Introduction
    • Company Details
      • Group Companies
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation News
  • TEVA PHARMACEUTICAL INDUSTRIES
    • Introduction
    • Company Details
      • Business strategy
      • Organisational structure
    • Products
      • Pharmaceutical Production
      • Raw materials for pharmaceutical production
      • Research and development
      • Generic Products
      • United States
      • Europe
      • Rest of the World
    • Branded products
      • Copaxone
      • Azilect
      • Biosimilars
    • Financials
      • Geographical breakdown
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation
  • WOCKHARDT
    • Introduction
    • Company Details
    • Products
    • Financials
    • Recent Developments
      • Recent Company News
      • Recent Litigation
  • ZYDUS CADILA
    • Introduction
    • Company Details
    • Products
      • Products updates for FY2011/12
    • Financials
    • Recent Developments
      • Recent Acquisitions
      • Recent Company News
      • Recent Litigation News

LIST OF TABLES

  • Fiscal Year Results, Listed by Sales
  • Fiscal Year Results for the last Five Years, Listed by Sales
  • EU-Approved Biosimilars, 2006-12
  • Major Shared Exclusivities, 2009-12
  • Least-Developed Countries
  • Members and dates of acceptance
  • Actavis: owned properties
  • Actavis: leased properties
  • Actavis: selected generic product portfolio, 2012
  • Actavis: selected brand product portfolio, 2012
  • Watson ANDA Approvals, January 2002 - December 2012
  • Actavis, ANDA Approvals January 2006 - December 2012
  • Actavis: fiscal year results, in US$ millions
  • Actavis: sales by region, in US$ millions
  • Actavis: sales by therapy area, in US$ millions
  • Actavis: product sales by segment, in US$ millions
  • Apotex ANDA Approvals, January 2002 - December 2012
  • Aspen Pharmacare Group at a glance
  • Aspen Pharmacare: fiscal year results, in R millions
  • Aspen Pharmacare: fiscal year results, in US$ millions
  • Aurobindo: regulatory filings as at 31st March 2012
  • Aurobindo ANDA Approvals, January 2002 - December 2012
  • Aurobindo: standalone fiscal year results, in Rs millions
  • Aurobindo: standalone fiscal year results, in US$ millions
  • Aurobindo: consolidated fiscal year results, in Rs millions
  • Aurobindo: consolidated fiscal year results, in US$ millions
  • Cipla ANDA Approvals, January 2002 - December 2012
  • Cipla: fiscal year results to 31st March in Rs millions
  • Cipla: fiscal year results to 31st March in US$ millions
  • Dr Reddy's ANDA Approvals, January 2002 - December 2012
  • Dr Reddy's Laboratories: Consolidated Fiscal Year Results, in Rs millions
  • Dr Reddy's Laboratories: Consolidated Fiscal Year Results, in US$ millions
  • Dr Reddy's Laboratories: Consolidated Fiscal Year Segment Results, in Rs millions
  • Dr Reddy's Laboratories: Consolidated Fiscal Year Results, in US$ millions
  • Egis: Sales of Pharmaceuticals by Therapy, in HUF millions
  • Egis: Sales of Pharmaceuticals by Therapy, in US$ millions
  • Egis: Leading Product Lines, 2011/12, in HUF millions and US$ millions
  • Egis ANDA approvals, January 2002 - December 2012
  • Egis: Fiscal Year Results, in HUF millions
  • Egis: Fiscal Year Results, in US$ millions
  • Egis: Fiscal Year Regional Sales Breakdown, in HUF millions
  • Egis: Fiscal Year Regional Sales Breakdown, in US$ millions
  • Hospira ANDA Approvals January 2004 - December 2012
  • Hospira: consolidated full year results, fiscal years ended 31st December, in US$ millions
  • Hospira: results by region, fiscal years ended 31st December, in US$ millions
  • Impax Laboratories ANDA Approvals, January 2002 - December 2012
  • Impax Laboratories: consolidated fiscal year results, in US$000s
  • Impax Laboratories: consolidated sales by division, in US$000s
  • Krka Group: number of Marketing Authorisations by region, 2007 - 2011
  • Krka Group: fiscal year results, in EUR 000s
  • Krka Group: fiscal year results, in US$000s
  • Krka Group: fiscal year results by region, in EUR 000s
  • Krka Group: fiscal year results by region, in US$000s
  • Krka Group: fiscal year results by product and service group, in EUR 000s
  • Krka Group: fiscal year results by product and service group, in US$000s
  • Lannett ANDA Approvals, January 2002 - December 2012
  • Lannett: Fiscal Year Results, in US$000s
  • Lannett: Fiscal Year Results by Therapy Area, in US$000s
  • Lannett: Fiscal Year Sales by Customer Category, in US$ millions
  • Lupin ANDA Approvals, January 2002 - December 2012
  • Lupin: Consolidated Fiscal Year Results, in Rs millions
  • Lupin: Consolidated Fiscal Year Results, in US$ millions
  • Mylan: global properties
  • Mylan: product sales by therapeutic category, in US$000s
  • Mylan ANDA Approvals, January 2002 - December 2012
  • Matrix Laboratories ANDA Approvals, January 2002 - December 2012
  • Bioniche Pharma ANDA Approvals, January 2002 - December 2012
  • Mylan: fiscal year results, in US$ millions
  • Mylan: fiscal year results by region, in US$000s
  • Mylan: segment results, in US$000s
  • Featured Products
  • Par Pharmaceutical ANDA Approvals, January 2002 - December 2012
  • Par Pharmaceutical Companies: Fiscal Year Results, in US$000s
  • Par Pharmaceutical Companies: Fiscal Year Results by Segment, in US$000s
  • Par Pharmaceutical Companies: Top Selling Products, in US$000s
  • Perrigo ANDA approvals, January 2002 - December 2012
  • Perrigo: Fiscal Year Results, in US$000s
  • Perrigo: Results by Division, in US$000s
  • Ranbaxy Laboratories: day one generic product launches in 2012
  • Ranbaxy Laboratories: leading branded products in 2012
  • Ranbaxy Laboratories: leading therapies in generic and branded markets in 2012
  • Ranbaxy ANDA Approvals, January 2002 -December 2012
  • Ohm Laboratories ANDA Approvals, January 2002 - December 2012
  • Ranbaxy Laboratories: consolidated fiscal year results, in Rs millions
  • Ranbaxy Laboratories: consolidated fiscal year results, in US$ millions
  • Gedeon Richter: main licensing partners, 2011
  • Gedeon Richter: main gynaecological products, 2011
  • Gedeon Richter: top ten products, in HUF millions
  • Gedeon Richter: top ten products in Hungary, in HUF millions
  • Gedeon Richter: own-developed compounds launched during 2011
  • Gedeon Richter: Licensed-in products launched during 2011
  • Gedeon Richter ANDA approvals, January 2002 - December 2012
  • Gedeon Richter: consolidated fiscal year results, in HUF millions
  • Gedeon Richter: consolidated fiscal year results, in US$ millions
  • Gedeon Richter: consolidated pharmaceutical segment results, in HUF millions
  • Gedeon Richter: consolidated pharmaceutical segment results, in US$ millions
  • Gedeon Richter: sales to top ten international markets, in Euro millions (Gedeon Richter figures)
  • Gedeon Richter: sales to top ten international markets, in US$ millions (Espicom figures)
  • Sandoz ANDA Approvals, January 2002 - December 2012
  • Sandoz: full year results, fiscal years ended 31st December, in US$ millions
  • Sawai Pharmaceutical: new products listed in November 2010 to June 2011
  • Sawai Pharmaceutical: new products listed in November 2011 to June 2012
  • Sawai Pharmaceutical: major products
  • Sawai Pharmaceutical: sales by therapeutic category, FY2011
  • Sawai Pharmaceutical: Fiscal Year Results, in \ millions
  • Sawai Pharmaceutical: Fiscal Year Results, in US$ millions
  • Simcere Pharmaceutical: Fiscal Year Results, in RMB000s
  • Simcere Pharmaceutical: Fiscal Year Results, in US$000s
  • Stada Arzneimittel: top five API sales in 2011, in EUR millions and US$ millions
  • Stada Arzneimittel: number of product launches per year
  • Stada Arzneimittel: fiscal year results, in EUR millions
  • Stada Arzneimittel: fiscal year results, in US$ millions
  • Stada Arzneimittel: fiscal year results by segment, in EUR millions
  • Stada Arzneimittel: fiscal year results by segment in US$ millions
  • Stada Arzneimittel: selected geographic segment data, in EUR millions
  • Stada Arzneimittel: selected geographic segment data, in US$ millions
  • Sun Pharmaceutical Industries ANDA Approvals, February 2006 - December 2012
  • Taro Pharmaceutical Industries ANDA Approvals, February 2010 - December 2012
  • Sun Pharmaceutical Industries: Consolidated Fiscal Year Results, in Rs millions
  • Sun Pharmaceutical Industries: Consolidated Fiscal Year Results, in US$ millions
  • Sun Pharmaceutical Industries: Consolidated Fiscal Year Results by Segment, in Rs millions and US$ millions
  • Teva Pharmaceutical Industries: principal operating subsidiaries
  • Teva Pharmaceutical Industries: principal pharmaceutical manufacturing facilities
  • Teva Pharmaceutical Industries: generics launched in the US, 2011
  • Teva ANDA Approvals January 2006 - December 2012
  • Barr Laboratories ANDA Approvals, January 2008 - December 2012
  • Pliva, Pliva Hrvatska and Pliva Lachema ANDA Approvals, January 2006 - December 2012
  • Teva Pharmaceutical Industries: fiscal year results, in US$ millions
  • Teva Pharmaceutical Industries: sales by geographical areas, in US$ millions
  • Wockhardt subsidiaries
  • Wockhardt ANDA Approvals, January 2002 - December 2012
  • Wockhardt: consolidated fiscal year results, in Rs millions
  • Wockhardt: consolidated fiscal year results, in US$ millions
  • Wockhardt: Consolidated Fiscal Year Results by Region, in Rs millions
  • Wockhardt: Consolidated Fiscal Year Results by Region, in US$ millions
  • Zydus Pharmaceuticals USA ANDA Approvals, January 2002 - December 2012
  • Zydus Cadila, consolidated fiscal year results, in Rs millions
  • Zydus Cadila, consolidated fiscal year results, in US$ millions

Volume 2: Industry Forecast

BMI INDUSTRY VIEW

INDUSTRY FORECAST

  • Africa
    • Algeria
    • Egypt
    • Ghana
    • Kenya
    • Nigeria
    • South Africa
    • Zimbabwe
  • Asia Pacific
    • Australia
    • Bangladesh
    • China
    • Hong Kong
    • India
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Pakistan
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe
    • Belarus
    • Belgium
    • Bulgaria
    • Croatia
    • Czech Republic
    • Estonia
    • France
    • Germany
    • Greece
    • Hungary
    • Italy
    • Kazahkstan
    • Latvia
    • Lithuania
    • Moldova
    • Netherlands
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • UK
    • Ukraine
    • Uzbekistan
  • Latin America
    • Argentina
    • Brazil
    • Chile
    • Colombia
    • Mexico
    • Peru
    • Puerto Rico
    • Venezuela
  • Middle East
    • Bahrain
    • Iran
    • Israel
    • Jordan
    • Kuwait
    • Lebanon
    • Morocco
    • Oman
    • Qatar
    • Saudi Arabia
  • UAE
  • North America
    • Canada
  • US

GLOSSARY

METHODOLOGY

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology

LIST OF TABLES

  • Algeria Generics Drug Market Indicators, Historical Data and Forecasts
  • Egypt Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales, 2009-2017
  • Kenya Generic Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales, 2009-2017
  • South Africa Generic Drugs Market Indicators, Historical Data And Forecasts
  • Cost Of Selected Drugs Post-Price Disclosure
  • Generic Drug Sales, 2009-2017
  • Bangladesh Generics Drug Market Indicators, Historical Data and Forecasts
  • China Generic Drug Sales Indicators 2009-2017
  • Generic Drug Sales Indicators, 2009-2017
  • Generic Drug Sales, 2009-2017
  • Indonesia Generics Drug Market Indicators, Historical Data and Forecasts
  • Generics Drug Market Indicators, Historical Data And Forecasts
  • Generic Drug Sales Indicators 2009-2017
  • New Zealand Generics Drug Market Indicators, Historical Data and Forecasts
  • Philippines Generics Drug Market Indicators, Historical Data and Forecasts, 2009-2017
  • Generic Drug Sales Indicators, 2009-2017
  • South Korea Generics Drug Market Indicators, Historical Data And Forecasts
  • Taiwan Generics Drug Market Indicators, Historical Data and Forecasts
  • Thailand Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales Indicators, 2009-2017
  • Belarus Generics Drug Market Indicators, Historical Data and Forecasts, 2009-2017
  • Generic Companies By Market Share, 2010
  • Belgium Generics Drug Market Indicators, Historical Data and Forecasts
  • Members Of Bulgarian Generic Pharmaceutical Manufacturers' Association (BGPharmA*), 2011
  • Bulgaria Generics Drug Market Indicators, Historical Data and Forecasts
  • Croatia Generic Drug Market Indicators, Historical Data And Forecasts, 2009-2018
  • Czech Generics Drug Market Indicators, Historical Data and Forecasts
  • Estonia Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017
  • France Generics Drug Market Indicators, Historical Data And Forecasts
  • Germany Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales, 2009-2017
  • Hungary Generics Drug Market Indicators, Historical Data and Forecasts
  • Kazakhstan Generics Drug Market Indicators, Historical Data and Forecasts, 2009-2017
  • Latvia Generics Drug Market Indicators, Historical Data and Forecasts
  • Lithuania Generics Drug Market Indicators, Historical Data and Forecasts
  • Moldova Generics Drug Market Indicators, Historical Data and Forecasts
  • Netherlands Generics Drug Market Indicators, Historical Data and Forecasts
  • Poland Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017
  • Portugal Generic Drug Market Indicators, Historical Data And Forecasts
  • Top Generic Drugs By Value In 2011
  • Average Price Of Top Generic Drugs By Value 2010-2011
  • Romania Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017
  • Russia Generics Drug Market Indicators, Historical Data And Forecasts
  • Serbia Generics Drug Market Indicators, Historical Data And Forecasts
  • Members Of GENAS, 2011
  • Generics Drug Market Indicators, Historical Data And Forecasts
  • Slovenia Generics Drug Market Indicators, Historical Data and Forecasts
  • Spain Generics Drug Market Indicators, Historical Data and Forecasts
  • Switzerland Generic Drug Market Indicators, Historical Data and Forecasts
  • Turkey Generics Drug Market Indicators, Historical Data And Forecasts
  • Prescriptions Written and Dispensed Generically in England by Value, 1996-11 (GBPmn)
  • Generic Prescribing Rates by Therapeutic Area in England, 2006-11 (% by Volume)
  • Generic Dispensing Rates by Therapeutic Area in England, 2006-11 (% by Volume)
  • UK Generics Drug Market Indicators, Historical Data and Forecasts
  • Generics Drug Market Indicators, Historical Data and Forecasts
  • Uzbekistan Generics Drug Market Indicators, Historical Data and Forecasts
  • Argentina Generics Drug Market Indicators, Historical Data And Forecasts
  • Brazil Generics Drug Market Indicators, Historical Data And Forecasts
  • Chile Generic Drug Market Indicators, Historical Data and Forecasts
  • Colombia Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales Indicators, 2009-2017
  • Peru Generics Drug Market Indicators, Historical Data and Forecasts
  • Puerto Rico Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales, 2009-2017
  • Bahrain Generics Drug Market Indicators, Historical Data And Forecasts
  • Israel Generics Drug Market Indicators, Historical Data And Forecasts
  • Jordan Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Sales Indicators, 2009-2017
  • Lebanon Generic Drug Market Indicators, Historical Data And Forecasts, 2009-2017
  • Morocco Generics Drug Market Indicators, Historical Data and Forecasts
  • Oman Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017
  • Qatar Generics Drug Market Indicators, Historical Data and Forecasts
  • Saudi Arabia Generics Drug Market Indicators, Historical Data And Forecasts
  • Generic Drug Sales Indicators, 2009-2017

LIST OF CHARTS

  • Top 30 Global Generic Drug Markets By Value (US$bn)
  • Top 30 Global Generic Drug Markets By Growth (local currency y-o-y 2012)
  • Top 30 Global Generic Drug Markets By Per-Capita Spending In 2012 (US$)
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2007-2022
  • Generic Drug Market Forecast 2009-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2009-2022
  • Generic Drug Market Forecast 2009-2022
  • Generic Drug Market Forecast 2007-2021
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2009-2022
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008-2022
  • Pakistan Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Market Forecast
  • Generic Drug Sales Forecast 2008-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2009-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • More Can Be Saved
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-20
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Italy Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drugs Market Forecast 2009-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2009-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast
  • Sweden Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Market Forecast 2008-2022
  • Switzerland: Market Share Of Companies Operating In The Generic Medicines Sector
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008 - 2022
  • Generic Drug Market Forecast 2008 - 2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008 - 2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast
  • Branded & Generic Pharmacy Sales Volume, 2001-2007
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast
  • Generic Drug Market Forecast 2008-2022
  • Generic Drug Market Forecast 2008 - 2022
  • Generics Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Market Forecast 2008-2022
  • US Generics Drug Market Indicators, Historical Data And Forecasts
Back to Top